Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY

$63.02

Updated: 03/11/2026, 13:44:14

Market Cap
$128.82B
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US

No historical data available

Company Profile

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

USD
NYSE
CEO: Christopher Boerner
Employees: 32,500
https://www.bms.com
Asset Summaries
Latest generated summaries for BMY

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
BMY-10-k-fy2025.html3.7 MBtext/htmlENFiled 11/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 45 KPI observations

Revenue

N/A

FY — · Reported

Net income

$7.1B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$12.8B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$5.2B

FY 2023 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Legacy Portfolio products
Growth Portfolio products
2025 regulatory approvals

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
5 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureUnited States manufacturing network · Manufacturing Partner Country · confidence 97%
Named headquarters Manufacturing partner country

Ireland manufacturing network

Ireland · Manufacturing Partner Country

97% confidence
Functions
Manufacturing, Supply Chain
Ownership
Outsourcing Partner
Products / scope
Not disclosed by country
Share of production
Not disclosed by country
Reported revenue share
Not disclosed by country
Significant manufacturing operations locations. We have significant manufacturing operations in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland.
Significant biologics, cell therapy and pharmaceutical manufacturing sites. Our significant biologics, cell therapy and pharmaceutical manufacturing facilities are located in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland

Ireland

Ireland manufacturing network

Our significant biologics, cell therapy and pharmaceutical manufacturing facilities are located in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland

Puerto Rico

Puerto Rico manufacturing network

Our significant biologics, cell therapy and pharmaceutical manufacturing facilities are located in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland

Switzerland

Switzerland manufacturing network

Our significant biologics, cell therapy and pharmaceutical manufacturing facilities are located in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland

the Netherlands

the Netherlands manufacturing network

Our significant biologics, cell therapy and pharmaceutical manufacturing facilities are located in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland

United States

United States manufacturing network

Our significant biologics, cell therapy and pharmaceutical manufacturing facilities are located in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Single-segment biopharmaceutical company

Single segment innovative medicines business focused on oncology, hematology, immunology, cardiovascular and neuroscience

99%
Source evidence
“We operate in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases.”

Company description

Global biopharmaceutical company discovering, developing and delivering innovative medicines

98%
Source evidence
“Bristol-Myers Squibb Company is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.”

Growth vs Legacy portfolio structure

Products organized into Growth Portfolio and Legacy Portfolio

96%
Source evidence
“Growth Portfolio Opdivo® Opdivo (nivolumab) is a biologic”

Customer and distribution channels

Products sold principally to wholesalers, distributors, specialty pharmacies, and to a lesser extent retailers, hospitals, clinics, government agencies and directly to patients

97%
Source evidence
“Our products are sold worldwide, principally to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, government agencies and directly to patients.”

U.S. distribution through wholesalers

Most U.S. products distributed through wholesalers; consolidation of pharmacy chains noted

95%
Source evidence
“in the U.S., most of our products are distributed through wholesalers, and if one of these wholesalers should encounter financial or other difficulties, we might be unable to timely collect the amounts that the wholesaler owes us”

U.S. wholesaler concentration

Three largest wholesalers account for ~87% of total gross sales of U.S. products in 2025

92%
Source evidence
“our three largest wholesalers, which account for approximately 87% of total gross sales of U.S. products for the year ended December 31, 2025”

REMS-restricted distribution programs

Camzyos, Revlimid and Pomalyst distributed through restricted REMS/risk-management programs in US; Revlimid and Imnovid internationally

93%
Source evidence
“Camzyos is only available through a restricted program called the Camzyos REMS Program.”

Legacy Portfolio products

Legacy Portfolio: Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel, Abraxane

98%
Source evidence
“Eliquis® Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF”

Growth Portfolio products

Growth Portfolio: Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati, Cobenfy

98%
Source evidence
“Opdivo® Opdivo (nivolumab) is a biologic and a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.”

2025 regulatory approvals

Multiple 2025 approvals across Breyanzi, Camzyos, Opdivo/Opdivo Qvantig, Opdivo+Yervoy, Augtyro, Inrebic in US, EU, Japan

93%
Source evidence
“In 2025, we have achieved multiple regulatory approvals across our portfolio”

Operations and dependencies

Significant manufacturing operations locations

Significant manufacturing operations in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland

98%
Source evidence
“We have significant manufacturing operations in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland.”

Significant biologics, cell therapy and pharmaceutical manufacturing sites

Significant biologics, cell therapy and pharmaceutical manufacturing facilities in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland

95%
Source evidence
“Our significant biologics, cell therapy and pharmaceutical manufacturing facilities are located in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland”

Third-party API/drug substance reliance for key products

Relies on third parties for all or a portion of API/drug substance for Eliquis, Opdivo, Pomalyst/Imnovid, Yervoy, Sprycel, Abraxane, Zeposia, Camzyos, Sotyktu, Krazati and Cobenfy

97%
Source evidence
“we rely on third parties to manufacture or supply us with all or a portion of the active product ingredient or drug substance necessary for us to manufacture various products, including Eliquis, Opdivo, Pomalyst/Imnovid, Yervoy, Sprycel, Abraxane, Zeposia, Camzyos, Sotyktu, Krazati and Cobenfy.”

Single/sole-source raw materials

Purchases some raw materials/components from one source or a single source, mitigated via inventory management and alternative sourcing

90%
Source evidence
“For some products, we purchase our raw materials, components and supplies from one source (the only source available to us) or a single source (the only approved source among many available to us)”

Employee base at December 31, 2025

Approximately 32,500 employees in 43 countries; 54% U.S. (ex-Puerto Rico), 46% outside U.S.

97%
Source evidence
“As of December 31, 2025, we had approximately 32,500 employees in 43 countries. Approximately 54% of our employees are located in the U.S. (excluding Puerto Rico) and 46% are located outside of the U.S.”

Positioning and strategy

2025 business development activities

2025: acquired Orbital Therapeutics; strategic collaboration with BioNTech; exclusive licensing agreement with Philochem

97%
Source evidence
“Our significant business development activities in 2025 included (i) the acquisition of Orbital Therapeutics, (ii) the execution of a global strategic collaboration agreement with BioNTech, and (iii) the execution of a global exclusive licensing agreement with Philochem.”

2025 business development transactions

Acquired Orbital Therapeutics; BioNTech pumitamig collaboration; Philochem OncoACP3 license; Indianapolis radiopharmaceutical facility

95%
Source evidence
“acquired Orbital Therapeutics, which provided the Company with full rights to OTX-201, a preclinical in vivo CAR T-cell therapy”

Cell therapy and radiopharmaceutical manufacturing investment

Investing in cell therapy manufacturing network (Bothell, Summit, Devens, Leiden) and opened new radiopharmaceutical facility in Indianapolis in 2025

95%
Source evidence
“During 2025, we completed the construction of a new state-of-the-art cell therapy manufacturing facility in Leiden, Netherlands. Additionally, we opened a new radiopharmaceutical facility in Indianapolis, Indiana during 2025.”

Competitive landscape

Competes with global research-based drug companies, smaller research companies, and generic drug manufacturers

95%
Source evidence
“We compete with other global research-based drug companies, many smaller research companies with more limited therapeutic focus and generic drug manufacturers.”

Company strategy priorities

Focus on transformational medicines, operational excellence, capital allocation for growth and shareholder returns; biopharma scale with biotech agility

95%
Source evidence
“Our priorities are to focus on transformational medicines where we have a competitive advantage, drive operational excellence throughout the organization and strategically allocate capital for long-term growth and shareholder returns.”

Vector technology dual sourcing and third-party manufacturing shift

Accelerating transition to new vector technologies with dual sourcing; expanding third-party manufacturer use for supply continuity

90%
Source evidence
“Longer-term, we are accelerating our plans to transition to new vector technologies with a dual sourcing strategy.”

Risks, financing, and outlook

2025 debt redemption

Early redemption of $8.7 billion long-term debt in 2025 with $356 million loss on debt redemption

93%
Source evidence
“Loss on debt redemption resulted from the early redemption of $8.7 billion long-term debt obligations in 2025.”

Revenue dynamics 2025 and 2026 outlook

Growth Portfolio/Eliquis demand offset by Legacy Portfolio generics; 2026 generic erosion expected primarily from Revlimid and Pomalyst

95%
Source evidence
“We expect continued generic erosion within our Legacy Portfolio in 2026 primarily due to Revlimid and Pomalyst in the U.S.”

Total revenues 2025 vs 2024

Total Revenues $48,194M (2025) vs $48,300M (2024), relatively flat

97%
Source evidence
“Total Revenues$48,194 $48,300”

U.S. Government Agreement (December 2025)

December 2025 U.S. Government Agreement: Medicaid Eliquis, API donation, ~80% DTC discounts, tariff relief until January 2029

95%
Source evidence
“BMS will receive certain U.S. tariff relief until January 2029 and will not be subject to future pricing mandates in the U.S.”

2025 impairment and Acquired IPRD charges

Impairment charges $1,098M (2025); Acquired IPRD $3,721M (2025), $13,373M (2024)

93%
Source evidence
“Impairment charges1,098 2,963 255”

IRA Medicare price setting

IRA-imposed Medicare maximum fair prices: Eliquis (2026), Pomalyst (2027); Orencia selected for 2028 negotiation

95%
Source evidence
“In August 2024, as part of the first round of government price setting pursuant to the IRA, the HHS announced the "maximum fair price" for a 30-day equivalent supply of Eliquis”

U.S. drug pricing measures (Public Health Service Act program)

State-level measures under the Federal Public Health Service Act drug pricing program could materially impact revenues and pricing practices

90%
Source evidence
“such measures could modify or decrease access, coverage, or reimbursement of our products, or result in significant changes to our sales or pricing practices, which could have a material impact on our revenues and results of operations.”

Key product concentration

Eliquis, Opdivo, Opdivo Qvantig, Orencia, Reblozyl and Yervoy expected to represent a significant percentage of revenue, earnings and cash flows during the next few years

98%
Source evidence
“We expect that Eliquis, Opdivo, Opdivo Qvantig, Orencia, Reblozyl and Yervoy will represent a significant percentage of our revenue, earnings and cash flows during the next few years.”

CAR-T T-cell malignancy boxed warning

FDA determined safety labeling changes including boxed warning for T-cell malignancy risk in CAR-T therapies (Jan 2024)

95%
Source evidence
“In January 2024, the FDA determined that safety labeling changes were needed for approved CAR-T cell therapies, including a "boxed warning" about the possible risk of T-cell malignancies in patients treated with CAR-T cell therapy.”

Generic/biosimilar erosion of exclusivity

Loss of market exclusivity leads to substantial and rapid declines in sales of the original innovative product

94%
Source evidence
“When these patent rights and other forms of exclusivity expire and generic versions of a medicine are approved and marketed, there are often substantial and rapid declines in the sales of the original innovative product.”

Cybersecurity and AI-related IT risk

Dependent on IT systems including AI programs; cybersecurity incidents growing in frequency, sophistication and intensity; AI regulatory landscape uncertain

90%
Source evidence
“We are dependent on information technology systems, including artificial intelligence programs, and face risk of cybersecurity incidents that could disrupt our business and result in theft of proprietary, confidential and personal information.”

Third-party performance risk

Reliance on third parties for research, development, manufacturing and commercialization poses contractual, regulatory and data-privacy failure risks

90%
Source evidence
“The failure of any critical third party to satisfactorily meet its obligations, including for future royalty and milestone payments; to adequately deploy business continuity plans in the event of a crisis; and/or to satisfactorily resolve significant disagreements with us or address other factors, could have a material adverse impact on our business and results of operations.”

Material exposure graph

Key growth products (Eliquis, Opdivo, Opdivo Qvantig, Orencia, Reblozyl, Yervoy)
Revenue Exposure

Majority of revenue and earnings derived from several key products; loss of market exclusivity or demand disruption would materially hurt cash flows.

Relevance 95·Dependency 85·Confidence 95
Source evidence
“We derive a majority of our revenue and earnings from several key products.”
Inflation Reduction Act (IRA)
Regulatory Exposure

IRA Medicare maximum fair prices apply to Eliquis (2026) and Pomalyst (2027); Orencia selected for 2028, potentially accelerating revenue erosion before IP expiry.

Relevance 95·Dependency 75·Confidence 95
Source evidence
“the HHS announced the "maximum fair price" for a 30-day supply of Pomalyst, which applies to the U.S. Medicare channel effective January 1, 2027”
Eliquis
Revenue Exposure

Eliquis demand increased 2025 revenues but faces IRA Medicare maximum fair price effective January 1, 2026 and Medicaid free supply under the U.S. Government Agreement.

Relevance 95·Dependency 75·Confidence 93
Source evidence
“Demand increased across the Growth Portfolio and for Eliquis, which was offset by the impact of generics across the remainder of the Legacy Portfolio”
United States
Revenue Exposure

U.S. government channel rebates, IRA price setting, tariffs, and the U.S. Government Agreement directly affect U.S. pricing, reimbursement and revenues.

Relevance 90·Dependency 75·Confidence 92
Source evidence
“These pressures have resulted in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse, which have negatively impacted”
Generic drug manufacturers
Competitive Exposure

Generic and biosimilar entry after loss of exclusivity causes substantial and rapid sales declines, a core competitive exposure.

Relevance 90·Dependency 70·Confidence 93
Source evidence
“We compete with other global research-based drug companies, many smaller research companies with more limited therapeutic focus and generic drug manufacturers.”
Eliquis
Revenue Exposure

Eliquis is a leading Legacy Portfolio product; its revenue contribution and eventual exclusivity loss materially affect results.

Relevance 90·Dependency 65·Confidence 90
Source evidence
“Eliquis® Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF”
Revlimid
Revenue Exposure

Revlimid generic erosion is a primary expected driver of 2026 Legacy Portfolio revenue decline; its acquired product right was fully amortized in Q4 2024.

Relevance 90·Dependency 65·Confidence 93
Source evidence
“We expect continued generic erosion within our Legacy Portfolio in 2026 primarily due to Revlimid and Pomalyst in the U.S.”
Opdivo
Revenue Exposure

Opdivo anchors the Growth Portfolio with multiple approved anti-cancer indications, including new subcutaneous Opdivo Qvantig/Opdivo SC formulations.

Relevance 90·Dependency 60·Confidence 90
Source evidence
“Opdivo QvantigTM Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) is a subcutaneously administered PD-1 inhibitor”
Wholesalers, distributors, specialty pharmacies
Customer Exposure

Products are principally sold through wholesalers, distributors and specialty pharmacies, concentrating channel risk.

Relevance 85·Dependency 85·Confidence 95
Source evidence
“Our products are sold worldwide, principally to wholesalers, distributors, specialty pharmacies”
Active product ingredient / drug substance
Supplier Dependency

Third parties supply all or part of API/drug substance for key products including Eliquis and Opdivo; supply interruption risk mitigated by inventory and back-up sourcing.

Relevance 85·Dependency 85·Confidence 95
Source evidence
“we rely on third parties to manufacture or supply us with all or a portion of the active product ingredient or drug substance necessary for us to manufacture various products, including Eliquis, Opdivo, Pomalyst/Imnovid, Yervoy, Sprycel, Abraxane, Zeposia, Camzyos, Sotyktu, Krazati and Cobenfy.”
U.S., Puerto Rico, Netherlands, Ireland, Switzerland
Manufacturing Dependency

BMS concentrates significant manufacturing operations in five locations, creating operational dependence on these sites.

Relevance 85·Dependency 80·Confidence 95
Source evidence
“We have significant manufacturing operations in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland.”
Three largest U.S. wholesalers
Customer Exposure

~87% of U.S. product gross sales flow through three wholesalers, concentrating U.S. channel risk and inventory-estimation reliance.

Relevance 85·Dependency 80·Confidence 92
Source evidence
“our three largest wholesalers, which account for approximately 87% of total gross sales of U.S. products for the year ended December 31, 2025”
Pomalyst
Revenue Exposure

Pomalyst faces U.S. generic erosion in 2026 and an IRA maximum fair price effective January 1, 2027; product right fully amortized Q4 2025.

Relevance 85·Dependency 60·Confidence 92
Source evidence
“the Pomalyst acquired marketed product right was fully amortized in the fourth quarter of 2025.”
Federal Public Health Service Act drug pricing program
Regulatory Exposure

State pricing measures under the program could decrease access, coverage or reimbursement and materially impact revenues.

Relevance 80·Dependency 75·Confidence 90
Source evidence
“such measures could modify or decrease access, coverage, or reimbursement of our products, or result in significant changes to our sales or pricing practices, which could have a material impact on our revenues and results of operations.”
U.S. pharmaceutical wholesalers
Customer Exposure

Most U.S. product revenue flows through wholesalers; wholesaler financial difficulty or pharmacy chain consolidation affects collections and revenue.

Relevance 75·Dependency 80·Confidence 95
Source evidence
“in the U.S., most of our products are distributed through wholesalers, and if one of these wholesalers should encounter financial or other difficulties, we might be unable to timely collect the amounts that the wholesaler owes us”
CAR-T cell therapies
Technology Dependency

BMS's platform portfolio depends on CAR-T cell therapies (Breyanzi, Abecma) alongside biologics, ADCs and radiopharmaceuticals.

Relevance 75·Dependency 55·Confidence 90
Source evidence
“Breyanzi (lisocabtagene maraleucel) is a CD19-directed genetically modified autologous CAR-T cell therapy”
Revlimid
Demand Driver

Revlimid is a Legacy Portfolio multiple myeloma product facing generic erosion dynamics typical of the legacy portfolio.

Relevance 75·Dependency 45·Confidence 88
Source evidence
“Revlimid® Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma.”
FDA CAR-T boxed warning
Regulatory Exposure

Safety labeling changes for CAR-T therapies (Breyanzi, Abecma) may limit patient population and reduce revenue.

Relevance 70·Dependency 60·Confidence 90
Source evidence
“In January 2024, the FDA determined that safety labeling changes were needed for approved CAR-T cell therapies, including a "boxed warning" about the possible risk of T-cell malignancies in patients treated with CAR-T cell therapy.”
OECD Pillar Two global minimum tax
Tax Exposure

Pillar Two legislation in operating jurisdictions may significantly impact BMY's tax provision and results of operations.

Relevance 65·Dependency 60·Confidence 85
Source evidence
“This includes Pillar Two legislation that has been enacted pursuant to the OECD/G20 Inclusive Framework in various jurisdictions in which we operate. These rules and associated legislative changes may significantly impact our tax provision and results of operations.”
Viral vector manufacturing technology
Technology Dependency

Cell therapy supply depends on vector supply; BMS is expanding third-party vector supply and transitioning to new vector technologies with dual sourcing.

Relevance 55·Dependency 55·Confidence 85
Source evidence
“we continue to partner with third party manufacturers to expand supply of vector and are investing in new facilities for drug product manufacturing. Longer-term, we are accelerating our plans to transition to new vector technologies with a dual sourcing strategy.”
Full company information
Latest profile, trading, valuation, and identifier data stored for BMY.
Share price
$63.02
Market cap
$128.82B
Exchange
NYSE
Currency
USD
CEO
Christopher Boerner
Employees
32,500
IPO date
01/06/1972
Beta
0.227
Last dividend
$0.00
Day range
$62.17 – $63.14
52-week range
$45.27 – $68.64
1-day performance
0.86%
1-year performance
39.21%
Current drawdown (1Y)
-8.19%
CIK
0000014272
CUSIP
110122108
ISIN
US1101221083
Created
07/12/2025, 03:03:03
Last update
03/11/2026, 13:44:14

Track Bristol-Myers Squibb Company with an AI analyst

See which prediction-market events move BMY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to BMY from your Railway `news_articles` table.

Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines?

Zacks Investment Research • STOCK • 12/06/2026, 16:20:31

Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial

Reuters • STOCK • 11/06/2026, 09:03:31

Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 09/06/2026, 23:42:10

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

Zacks Investment Research • STOCK • 05/06/2026, 20:46:12

Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?

Fool - Investing News • STOCK • 04/06/2026, 04:30:00

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research • STOCK • 03/06/2026, 12:00:41

BMY Gets Opdivo Label Expansion in the EU, Update on Camzyos

Zacks Investment Research • STOCK • 02/06/2026, 16:01:14

Bristol Myers Squibb: This Pullback Is A Gift For Long-Term Investors

Seeking Alpha • STOCK • 02/06/2026, 12:59:47

Bristol Myers' Growth Portfolio Just Overtook The Legacy One

Seeking Alpha • STOCK • 02/06/2026, 06:23:46

Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks

Fool - Investing News • STOCK • 02/06/2026, 01:15:00

Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO

Zacks Investment Research • STOCK • 01/06/2026, 13:01:12

Bristol Myers drug delays myeloma progression in hard to treat patients

Reuters • STOCK • 29/05/2026, 10:02:13